{"docstore/metadata": {"0144ffc7-1b3b-425c-876f-869a0e13f407": {"doc_hash": "c02d545a5a8440ab77d2099bf9eef7dc67f17644a665ab363f4ca31b32763fb3"}, "1e67250b-b33f-4159-b9bf-e42a6567f13c": {"doc_hash": "944e71a7688f7048a18b759baed0ad7348a844febfe8a6b43c70701d10797b63"}, "e519d84d-856d-41aa-aab1-05bdfa356c9a": {"doc_hash": "d425f8b46b894c9a6ca370871806b8d1a054499e8974e1c89c68eb4b382e9b0f"}, "043dddec-9a5a-419b-a155-743b9ef086ec": {"doc_hash": "66f39b4aec496aa7c9767ca20a90231661a378d5f47d6b6eaa0038d4be74644a", "ref_doc_id": "0144ffc7-1b3b-425c-876f-869a0e13f407"}, "7c07b0f7-c628-44c1-92ff-300286110f11": {"doc_hash": "808010b0661ffadb9b4d3e68c011a81075eb2561bb6049de2a753357af4fa6ea", "ref_doc_id": "1e67250b-b33f-4159-b9bf-e42a6567f13c"}, "2b8efcdc-0b5a-4888-8dfe-97e9d45d0a23": {"doc_hash": "11b1877ab05ddf588a4f8822dd2a985f34b93f949825a545a115f8ad7607d91c", "ref_doc_id": "e519d84d-856d-41aa-aab1-05bdfa356c9a"}}, "docstore/data": {"043dddec-9a5a-419b-a155-743b9ef086ec": {"__data__": {"id_": "043dddec-9a5a-419b-a155-743b9ef086ec", "embedding": null, "metadata": {"version": "v1"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0144ffc7-1b3b-425c-876f-869a0e13f407", "node_type": "4", "metadata": {"version": "v1"}, "hash": "c02d545a5a8440ab77d2099bf9eef7dc67f17644a665ab363f4ca31b32763fb3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Drug X-101: Shows 75% efficacy in Phase II trials for Alzheimer's", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 65, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7c07b0f7-c628-44c1-92ff-300286110f11": {"__data__": {"id_": "7c07b0f7-c628-44c1-92ff-300286110f11", "embedding": null, "metadata": {"version": "v1"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1e67250b-b33f-4159-b9bf-e42a6567f13c", "node_type": "4", "metadata": {"version": "v1"}, "hash": "944e71a7688f7048a18b759baed0ad7348a844febfe8a6b43c70701d10797b63", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Compound Y-202: Potential neuroprotective effects observed in mice models", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 73, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b8efcdc-0b5a-4888-8dfe-97e9d45d0a23": {"__data__": {"id_": "2b8efcdc-0b5a-4888-8dfe-97e9d45d0a23", "embedding": null, "metadata": {"version": "v1"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e519d84d-856d-41aa-aab1-05bdfa356c9a", "node_type": "4", "metadata": {"version": "v1"}, "hash": "d425f8b46b894c9a6ca370871806b8d1a054499e8974e1c89c68eb4b382e9b0f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Drug Z-303: FDA approval pending for Phase III trials in Parkinson's", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 68, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"0144ffc7-1b3b-425c-876f-869a0e13f407": {"node_ids": ["043dddec-9a5a-419b-a155-743b9ef086ec"], "metadata": {"version": "v1"}}, "1e67250b-b33f-4159-b9bf-e42a6567f13c": {"node_ids": ["7c07b0f7-c628-44c1-92ff-300286110f11"], "metadata": {"version": "v1"}}, "e519d84d-856d-41aa-aab1-05bdfa356c9a": {"node_ids": ["2b8efcdc-0b5a-4888-8dfe-97e9d45d0a23"], "metadata": {"version": "v1"}}}}